Navigation Links
Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
Date:3/1/2011

WALTHAM, Mass., March 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response. The trial, to be conducted under a Cooperative Research and Development Agreement (CRADA) executed between the NCI and Syndax, will investigate whether patient tumors can be reprogrammed to express estrogen receptor and render them to be sensitive to hormonal agents. This trial is based on animal data being published in the March 1, 2011, issue of Cancer Research.

Laboratory studies by Dr. Angela Brodie, professor of pharmacology and experimental therapeutics, and Gauri J. Sabnis, Ph.D., assistant professor of pharmacology and experimental therapeutics at the University of Maryland School of Medicine, in collaboration with Saraswati Sukumar, M.S., Ph.D., professor of oncology and pathology at the Johns Hopkins University School of Medicine, provided the basis for the phase 2 clinical trial. Their work demonstrates that entinostat induces hormone sensitivity in an animal model of triple negative breast cancer and that the combination with aromatase inhibitors prevents tumor growth as well as tumor metastasis.

"In the pre-clinical study that is being published in Cancer Research we demonstrated that entinostat can induce re-expression of estrogen receptor and aromatase in triple negative breast cancer cell lines and render them sensitive to an aromatase inhibitor," said Saranya Chumsri, M.D., assistant professor of medicine at the University of Maryland School of Medicine and a medical oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, principal investigator
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
2. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
3. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
6. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
7. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
8. K-V Pharmaceutical Company Announces $200 Million Private Debt Offering
9. Dehaier Medical Announces March Investor Presentations
10. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
11. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 KaloBios Pharmaceuticals, ... of Ronald A. Martell , to the position ... member of the KaloBios Board of Directors. In this ... senior management team to refine and execute on the ... antibody company developing therapeutics for orphan oncology indications with ...
(Date:5/28/2015)... May 28, 2015  CytomX, a biotechnology company developing ... that Sean McCarthy , D. Phil., chief executive ... Global Healthcare Conference in New York ... 2, 2015. Dr. McCarthy will provide an overview of ... and Probody drug conjugate programs. About CytomX ...
(Date:5/28/2015)... DIEGO and CAMBRIDGE, Mass., May 28, 2015 ... is investigating whether certain officers and ... fiduciary duties to shareholders.  Eleven Biotherapeutics is a ... and development of protein therapeutics to treat eye ... .   View this press ...
Breaking Medicine Technology:KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced today that Arthur ... executive officer, will present at the Morgan Stanley Global ... 14, 2011 at 9:10 a.m. Eastern Time.  Dr. Sands ...
... Sept. 5, 2011 Reportlinker.com ... research report is available in ... Facial Aesthetics (Botox, Dermal Fillers, ... Competitive Landscape and Market Forecasts ...
Cached Medicine Technology:Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference 2Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Facial Aesthetics (Botox, Dermal Fillers, Collagen) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 Park Cities ... Group Dog Training class starting Saturday, June 6th ... the courtyard of 5831 McCommas Blvd in Dallas, with a ... classes will run for five weeks, with no class being ... the class is $135. , In this Intermediate-to-Advanced level class, ...
(Date:5/28/2015)... Three years ago, Dr. Jeffrey Gosin announced ... Vascular & Vein Center! Dr. Gosin’s center is ... is his mission to provide the highest quality care in ... Dr. Jeffrey Gosin is Board Certified in Surgery and Vascular ... and Jefferson Medical College. He completed a General Surgery residency ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... 28, 2015 ISMETT , a leading ... boosted the Sicilian economy by €132.5 million in expenditure in ... of more than €73 million by retaining patients who otherwise ... a new study by the Battelle Memorial Institute. At the ... training and advanced health care management that is transforming Sicily ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3
... Holohan HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... of chickenpox-related hospitalizations in the United States for the first ... And a second study has found that the ... Centers for Disease Control and Prevention in 2006, may offer ...
... doses of the varicella, or chickenpox, vaccine provide excellent protection ... severe disease. To be published in the February 1 issue ... support the two-dose vaccine regimen recommended in the United States ... study online.) The Centers for Disease Control and Prevention ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Up ... an increase that translates into many fewer injuries and deaths ... the first state law requiring seat belts was passed in ... But now, according to the U.S. Centers for Disease Control ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- ... of the drug Avastin to treat breast cancer, a new ... odds of congestive heart failure in these patients. The ... Clinical Oncology , included almost 4,000 patients and found a ...
... DURHAM, N.C. A tiny light source and sensors at ... way to identify pre-cancerous cells in the lining of the ... successfully tested on patients during a clinical trial at the ... the promise of being a less invasive method for testing ...
... there is often concern about possible effects on the ... birth defects (thalidomide being a notorious example), and others ... about most drugs, level of risk. Researchers in the ... preclinical model for predicting a drug,s teratogenicity (tendency to ...
Cached Medicine News:Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 2Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 3Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 4Health News:Study confirms 2 vaccine doses protect children from chickenpox 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 3Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Detecting esophageal cancer with light 2Health News:Model predicts a drug's likelihood of causing birth defects 2
... The Techne TC-512 has a graphical touch ... your experiments at the "touch of a ... Wide linear gradient, Touch Screen, Graphical Display, ... Performance, Versatile Block Format, Intuitive Programmin, Free ...
... Techne TC412 is a high performance, high sample ... Features & Benefits include: Flexible block format, ... 8 peltiers, PC networking. Includes a four ... 32 Techne cyclers can be connected and run ...
... a compact design for personal use, yet is able ... up to 32 samples simultaneously. It contains a heating ... to add mineral oil to prevent evaporation of the ... and up to 15 steps can be freely connected ...
... cycler is the smallest footprint two-bay thermal ... ever before. The Disciple instrument ... communications to a computer using a remote ... thermal cycler contains the latest in power ...
Medicine Products: